EMT transcription factor ZEB1 alters the epigenetic landscape of colorectal cancer cells

Pablo Lindner1,2, Susmita Paul3, Markus Eckstein1, Chuanpit Hampel1,2, Julienne K. Muenzner1,2, Katharina Erlenbach-Wuensch1, Husayn P. Ahmed4, Vijayalakshmi Mahadevan4, Thomas Brabletz5, Arndt Hartmann1, Julio Vera3 and Regine Schneider-Stock1,2

Abstract
Epigenetic deregulation remarkably triggers mechanisms associated with tumor aggressiveness like epithelial–mesenchymal transition (EMT). Since EMT is a highly complex, but also reversible event, epigenetic processes such as DNA methylation or chromatin alterations must be involved in its regulation. It was recently described that loss of the cell cycle regulator p21 was associated with a gain in EMT characteristics and an upregulation of the master EMT transcription factor ZEB1. In this study, in silico analysis was performed in combination with different in vitro and in vivo techniques to identify and verify novel epigenetic targets of ZEB1, and to proof the direct transcriptional regulation of SETD1B by ZEB1. The chorioallantoic-membrane assay served as an in vivo model to analyze the ZEB1/SETD1B interaction. Bioinformatical analysis of CRC patient data was used to examine the ZEB1/SETD1B network under clinical conditions and the ZEB1/SETD1B network was modeled under physiological and pathological conditions. Thus, we identified a self-reinforcing loop for ZEB1 expression and found that the SETD1B associated active chromatin mark H3K4me3 was enriched at the ZEB1 promoter in EMT cells. Moreover, clinical evaluation of CRC patient data showed that the simultaneous high expression of ZEB1 and SETD1B was correlated with the worst prognosis. Here we report that the expression of chromatin modifiers is remarkably dysregulated in EMT cells. SETD1B was identified as a new ZEB1 target in vitro and in vivo. Our study demonstrates a novel example of an activator role of ZEB1 for the epigenetic landscape in colorectal tumor cells.

Introduction
Activation of a partial epithelial–mesenchymal transition (EMT) is a crucial cellular process for invasion and metastasis1. During EMT, epithelial cells lose cell–cell junctions, reorganize the cytoskeleton, gain a spindle-shaped morphology and increase cell motility. EMT in epithelial cancer can be found in invading cells mostly at the tumor invasion front with a loss of E-cadherin and sometimes an upregulation of Vimentin reflecting their high differentiation plasticity2. Such cells likely represent the most aggressive clones in a tumor that are responsible for malignant progression and metastasis.

A small group of pleiotropic transcription factors is responsible for the regulation of the EMT program. The double zinc finger and homeodomain factor ZEB1 is one of the most potent EMT-activators3,4 that is associated with aggressive behavior, metastasis, treatment resistance, and poor prognosis in different cell types5,6. It has been shown that ZEB1 represses the expression of epithelial genes and that this ability is an important feature for metastasis6–9. Since EMT is a highly complex, but reversible phenomenon, it seems to be logic that epigenetic mechanisms such as DNA methylation or chromatin alterations must be involved in EMT regulation.

So far, there are only few reports on how ZEB1 is associated with chromatin regulation. In fact, ZEB1
inhibits gene expression not only by direct DNA binding, but also by forming a repressor complex with Sirt1, a class III histone deacetylase (HDAC), to bind the promoter of E-cadherin, leading to E-cadherin expression silencing and the induction of EMT in prostate and pancreatic cancer cells\textsuperscript{[10,11]}. ZEB1 might recruit the histone deacetylase HDAC1 or the methyltransferase DNMT1 to the E-cadherin promoter to repress its transcription and maintain its hypermethylation status, respectively\textsuperscript{[11]}. Nevertheless, if ZEB1 can directly regulate the expression of chromatin modification enzymes and if these chromatin modifiers are essential for the progression or inhibition of EMT has remained widely elusive.

Recently, it has been reported that the cyclin-dependent kinase inhibitor p21 (\textup{p21\textsuperscript{\textup{Capp1/\textup{WAF1}}}~}) prevents EMT in tumors through inhibiting the expression and activity of the EMT transcription factor ZEB1\textsuperscript{[12]}. Here, p21 knockout cells (\textup{p21\textsuperscript{−/−}}) have been described to undergo a partial EMT showing a phenotypic heterogeneity and cellular plasticity with mesenchymal and epithelial characteristics. Yet, while EMT has been largely examined by examining “pure” epithelial or mesenchymal states, transient phenotypes still remain poorly understood, mainly because they are quite difficult to capture in vivo\textsuperscript{[13]}. Thus, the p21 knockout model is a suitable system to identify novel players of EMT with relevance in cancer progression and therapy.

In this study, we report on an epigenetically regulated, self-reinforcing loop for ZEB1-mediated EMT regulation, when the cell cycle inhibitor p21 is lost. For the first time, we describe a ZEB1-dependent dysregulation of chromatin modifiers in vitro and in vivo in the chicken CAM model. Furthermore, we show that there seems to be an active role of ZEB1 in shaping the epigenetic landscape to realize the EMT associated gene expression signature.

Materials and methods

Cell culture

For details, please see the Supplementary methods. The following cell lines were used: HCT116 (HCT WT, HCT \textup{p21\textsuperscript{−/−}}, HCT \textup{p53\textsuperscript{−/−}}) and DLD-1 (DLD-1 WT, DLD-1 \textup{p21\textsuperscript{−/−}}). Cells were cultured at 37 °C with 5% CO\textsubscript{2}. Mycoplasma free status was verified. All cell lines were authenticated using multiplex cell authentication by multiplexion (Heidelberg, Germany). Phase-contrast images were acquired using Leica instruments (Leica, Wetzlar, Germany). Images were edited with Adobe PhotoShop CS5 (Adobe Systems Inc., DW, USA) and ImageJ software (National Institute of Health, USA).

Collection of cell pellets

A detailed depiction is placed in the Supplementary methods. Cells were washed, scraped off the culture dish and transferred into sterile tubes. Cells were centrifuged and divided for protein (~60%), DNA (~10%) and RNA (~30%) preparation. Cell pellets were frozen in liquid N\textsubscript{2} and stored at −80 °C.

Western blotting

A detailed protocol with a list of used antibodies can be found in the Supplements. Briefly, protein lysates were separated by SDS-PAGE and blotted on nitrocellulose membranes overnight. Protein bands were detected, and images were processed using Adobe PhotoShop CS5 (Adobe Systems Inc., DW, USA) and ImageJ software (National Institute of Health, USA). Ratios were calculated against the house keeper GAPDH.

RNA expression analysis

Detailed descriptions and protocols can be found in the Supplements. Briefly, from total RNA a reverse transcription was executed, and cDNA amplification was accomplished with gene-specific primers and SYBR\textsuperscript{*} Green based kits using the CFX96\textsuperscript{TM} Real-Time System (Bio-Rad, Munich, Germany). A list of primers for RT-qPCR and gene lists for RT\textsuperscript{2} Profiler PCR Arrays (Qiagen, Hilden, Germany) can be found in the Supplementary information. Expression values were normalized to human B2M or GAPDH expression and given as relative fold expression compared to respective controls.

ZEB1 and SETD1B knock-down—siRNA transfection

A detailed description and the used siRNA sequences can be found in the Supplements. In short, cells were transfected and collected as described before at 24 and 48 h after transfection start. Transfection experiments were performed as recently explained\textsuperscript{[14]}.

ZEB1 overexpression—plasmid transfection

A detailed description can be found in the Supplements. Briefly, cells were transfected for 6 h and collected at 24 and 48 h. Transfection experiments were performed as recently explained\textsuperscript{[14]}.

Immunohistochemistry

A set of detailed protocols for antibody staining and antibody dilutions can be found in the Supplements. Briefly, FFPE sections were deparaffinized, rehydrated and stained for HE or with different antibodies. Bright field images were taken using Olympus instruments (Olympus Corporation, Shinjuku, Japan).

Immunohistochemistry—assessment of mitoses

A detailed description can be found in the Supplementary. Briefly, HE stained FFPE sections were digitized and five high power fields (HPF) per slide were analyzed and compared between HCT WT and HCT \textup{p21\textsuperscript{−/−}} cells.
Co-immunoprecipitation

Co-immunoprecipitation was performed according to the manufacturer's protocol and the following kit was used: Dynabeads® Protein G Immunoprecipitation Kit (Thermo Fischer, Waltham, USA; #10007D). Briefly, cell lysates (1000 μg per sample) were incubated with the primary antibodies over night at 4 °C with rotation. Following primary antibody was used: SETD1B (Abcam, Cambridge, UK; #ab113984; 10 μg per sample). The next day, the targets were eluted and stored for further use or directly analyzed by western blotting as recently described.

Proximity ligation assay (PLA)

The PLA was performed according to the manufacturer's manual and the following reagents were used: Duolink™ In Situ Detection Reagents Red (Sigma-Aldrich, Darmstadt, Germany; #DUO92008-100RXN), Duolink™ In Situ PLA™ Probe Anti-Mouse PLUS (Sigma-Aldrich, Darmstadt, Germany; #DUO92001-100RXN) and Duolink™ In Situ PLA™ Probe Anti-Rabbit MINUS (Sigma-Aldrich, Darmstadt, Germany; #DUO92005-100RXN). In short, the cells were co-stained over night at 4 °C using the following antibodies: SETD1B (Abcam, Cambridge, UK; #ab113984; 1:1000) and ZEB1 (R&D Systems, Cambridge, UK; #ab113984; 10 μg/ml). The next day, the PLA probe solution was added to the cells as described in the protocol. After the ligation and amplification steps, the nuclei were stained using Pro-Long® Gold Antifade reagent (Life Technologies, Darmstadt, Germany). Detection was performed using a Nikon Eclipse Ti-S fluorescence microscope (Nikon, Tokyo, Japan).

Chromatin-immunoprecipitation (ChIP)

A detailed protocol with lists of used antibodies, respective dilutions, and primers was given in the Supplements. Briefly, ChIP was performed using the ChiP-IT High Sensitivity™ kit (Active Motif, La Hulpe, Belgium). Samples were analyzed by qPCR as previously described. A summary of analyzed gene regions is depicted in the Supplementary methods. Fold enrichment against the IgG control was calculated as previously described.

Immunofluorescence

Details were given in the Supplements. In brief, HCT cells were used for staining of F-Actin filaments and cells were mounted on object slides with ProLong® Gold Antifade reagent (Life Technologies, Darmstadt, Germany). Confocal images were acquired using Carl Zeiss instruments (Carl Zeiss AG, Oberkochen, Germany). Images were edited using ZEN imaging software, Adobe PhotoShop CS5 and ImageJ software.

Chorioallantoic membrane (CAM) assay

This method was performed as previously described and a detailed protocol is given in the Supplementary information. In short, fertilized eggs were opened at day 8 of embryonic development and resealed with sterile tape. On day 9, HCT cell lines (embedded in Matrigel) were placed onto the CAM. In ovo xenografts were further incubated for 5 days and tumor size was documented. Cells were used for IHC (FFPE) and protein/RNA analyses (fresh frozen).

Bisulfite conversion and pyrosequencing analysis

A detailed protocol of the bisulfite conversion, the pyrosequencing methods, and the primer sequences can be found in the Supplement.

Structural modeling of protein–protein interactions

Elaborate descriptions of protein modeling were placed in the Supplements. The following mathematical tools were used: MODELLER17, ITASSER18, ClusPro19,20, PIC21, and CHIMERA22.

Bioinformatic workflow

A comprehensive explanation of the workflow was given in the Supplements. In brief, the distance between HCT116 cell lines was calculated using the Pearson correlation dissimilarity measure. Genome wide search for possible ZEB1 targets was performed using the TRANSFAC® database (BIOBASE GmbH, Wolfenbüttel, Germany; Version 2015.3). Genes potentially regulated by p21 and ZEB1 were identified by combining the statistical PCR Array Dataset analysis and the TRANSFAC® data.

Statistical analyses

A detailed summary of the statistical analyses and the used patient data sets can be found in the Supplements.

Results

ZEB1 initiates EMT in p21 knockout cells

Epigenetic alterations such as DNA methylation and posttranslational modifications of histone proteins are crucial for the EMT program. To identify how the EMT transcription factor ZEB1 cooperates with chromatin to trigger the EMT program we first defined an appropriate in vitro model. Recently, it has been shown by Li et al. that loss of the cell cycle inhibitor p21 leads to a more mesenchymal phenotype in HCT116 (HCT) cells. So first, we confirmed the spindle-shaped cell type by immunofluorescence staining for F-Actin (Supplementary Fig. S1A).

We could also verify a significant upregulation of Vimentin and ZEB1 as well as a significant decrease of E-Cadherin in a fraction of p21 knockout (p21−/−) cells (Supplementary Fig. S1B, C). Thus, we suggest that
p21−/− cells have undergone a partial EMT showing a phenotypic heterogeneity and cellular plasticity with mesenchymal and epithelial characteristics. For this reason we further used the HCT116 p21−/− cells as an EMT model to investigate epigenetic ZEB1 signaling.

To identify chromatin modifying enzymes that are regulated in p21−/− cells we used a cDNA array with 84 different chromatin modifiers (Qiagen, PAHS-085Z). Since p21 is the major transcriptional target of the tumor suppressor p53, we also included HCT p53−/− cells to eliminate any p53 driven effects. The heatmap clustergramm (Fig. 1a) and hierarchical clustering (Fig. 1b) using the Pearson correlation dissimilarity as a measure to calculate the distance between the three different cell lines showed that the HCT WT and HCT p53−/− cells highly overlap in their gene expression pattern. Interestingly, gene expression pattern of HCT p21−/− cells differed remarkably from that of HCT WT and HCT p53−/− cells. In contrast to others,24,25, HCT p53−/− cells show a cobble-stone like morphology and the expression levels of Vimentin or ZEB1 were comparable to the levels in HCT p53−/− cells as an EMT model to investigate epigenetic ZEB1 signaling.

In accordance with this finding, Western blot analysis showed that ZEB1 overexpression led to a significant increase in expression of ZEB1 at 24 h after siRNA transfection on the mRNA level and at 48 h on the protein level. Moreover, H3K4me3 protein level was also downregulated after siRNA transfection (Fig. 2a, b). Indeed, we observed a significant downregulation of ZEB1 at 24 h after siRNA transfection on the mRNA level and at 48 h on the protein level. Moreover, H3K4me3 protein level was also downregulated after siRNA transfection (Fig. 2a, b). In accordance with this finding, Western blot analysis showed that ZEB1 overexpression led to a significant increase in expression of ZEB1 and its associated protein levels accompanied by a loss in spindle cell morphology with a shift into more cobble stone like morphology although the Vimentin protein levels did not change (Fig. 2b, d).

Finally, chromatin immunoprecipitation (ChIP) analysis demonstrated an enrichment of ZEB1 at the E-Box containing promoter region of SETD1B (Fig. 2e, f). This binding was significantly reinforced in p21−/− EMT cells but not at a distant region downstream of the transcription site that does not contain an E-box element (Fig. 2e, f). For the first time, we show in vitro that the chromatin modifier SETD1B is a direct transcriptional target of ZEB1. This is a very remarkable finding as ZEB1 has been shown to mainly act as a transcriptional repressor of epithelial genes. Hence, our findings provide another example for ZEB1 as an inducer of gene transcription.
Since 2D culture fails to reflect the architectural features of native tissues mainly without considering the effects of extracellular matrix, we investigated if ZEB1 is also able to regulate SETD1B and its corresponding active histone mark in vivo. We used the chorioallantoic membrane (CAM) assay (Fig. 3a). When evaluating CAM xenografts we observed that HCT p21\(^{-/-}\) cells formed more aggressive tumors with larger size, an infiltrative growing pattern at the invasion front, and higher proliferation rate (Fig. 3a–c). We then performed immunostainings for p21 and ZEB1, in formalin-fixed and paraffin embedded CAM xenografts of HCT WT and HCT p21\(^{-/-}\) cells (Fig. 3d). Xenografts of p21\(^{-/-}\) cells showed higher ZEB1 staining scores compared to HCT WT cells when scoring the staining intensity (Fig. 3e).

In HCT WT cells ZEB1 was slightly expressed only in single cells, thus a score = Null has never been reached. Since no suitable antibody for immunostaining of SETD1B was available we analyzed SETD1B by RT-qPCR and western blot analysis of freshly prepared CAM xenograft samples (Fig. 3f, h). Its corresponding H3K4me3 code was also investigated by western blotting (Fig. 3g, h).
We verified the high expression of ZEB1 and SETD1B in p21−/− xenografts as observed in vitro. As expected there was a significant upregulation of the H3K4me3 code in EMT cells (Fig. 3g, h).

In a next step, we analyzed the set of upregulated and downregulated chromatin modifying enzymes (CMEs) summarized in Table 1 using the STRING database to better understand the connections between the individual CMEs. We included ZEB1 into the analysis in order to highlight already established or predicted interactions between ZEB1 and our targets of interest (Supplementary Fig. S1D, E). Although some links between several CMEs exist, so far ZEB1 mediated interactions with chromatin modifiers have not been validated.

Furthermore, we increased the clinical data set using the 944 colon cancer patients from the consensus molecular subtype study28. First, we found a high and significant correlation between ZEB1 and SETD1B (rS = 0.523, p < 0.001) in this tumor group. Second, we confirmed that SETD1B and ZEB1 showed indeed highest expression levels in the mesenchymal CMS4 subtype (Fig. 4a).

To further examine the prognostic value of ZEB1/SETD1B axis in colon cancer patients, we investigated a data set of 177 patients with colorectal carcinoma (GEO DataSet: GSE17536) (Fig. 4b–d). First, we defined a high and low expressing group using the median value for each parameter. Patients who had tumors with high ZEB1 expression had a worse prognosis than those having tumors with low ZEB1 expression (logrank p = 0.003, Fig. 4b). After 5 years, patients affected by tumors with high ZEB1 and those with low ZEB1 had overall survivals of 56 and 78.9%, respectively. SETD1B did not show clinical relevance in Kaplan–Meier analysis (Fig. 4c).

### Table 1 Dysregulated genes in HCT116 p21−/− cells compared to HCT116 WT cells.

| Gene        | Unigene no. | RefSeq no. | Fold Change | p-value  | Function                      | Active/repressive code |
|-------------|-------------|------------|-------------|----------|-------------------------------|------------------------|
| **A: upregulated genes** |             |            |             |          |                               |                        |
| DOT1La      | Hs.713641   | NM_032482  | 1.6625      | 0.02893  | Histone methyltransferase     | Repressive             |
| DZIP3b      | Hs.409210   | NM_014648  | 1.7171      | 0.02113  | Histone ubiquitination        | Repressive             |
| KMT2A       | Hs.258855   | NM_005933  | 1.5583      | 0.01501  | Histone methyltransferase     | Active                 |
| RPS6KA3d    | Hs.445387   | NM_004586  | 1.7695      | 0.01638  | Histone phosphorylation       | Active                 |
| SETD1B      | Hs.507122   | NM_015048  | 1.7331      | 0.00850  | Histone methyltransferase     | Active                 |
| SETD2f      | Hs.517941   | NM_014159  | 1.4879      | 0.01639  | Histone methyltransferase     | Active                 |
| **B: downregulated genes** |         |            |             |          |                               |                        |
| AURKBg      | Hs.442658   | NM_004217  | −2.25532    | 0.00003  | Histone phosphorylation       | Active                 |
| DNMT3Bh     | Hs.713611   | NM_006892  | −2.17850    | 0.00497  | DNA Methyltransferase         | Repressive             |
| ESCO2i      | Hs.99480    | NM_00107420| −2.77663    | 0.00497  | Histone acetyltransferase     | Active                 |
| HAT1l       | Hs.632532   | NM_003642  | −2.05623    | 0.00621  | Histone acetyltransferase     | Active                 |
| HDAC1k      | Hs.88556    | NM_004964  | −2.05148    | 0.03049  | Histone deacetylase           | Repressive             |
| HDAC5l      | Hs.3352     | NM_001527  | −3.76678    | 0.00621  | Histone deacetylase           | Repressive             |
| HDAC11m     | Hs.744132   | NM_024827  | −2.00926    | 0.00377  | Histone deacetylase           | Repressive             |
| RPS6KA5n    | Hs.510225   | NM_004755  | −2.06098    | 0.00621  | Histone phosphorylation       | Active                 |
| SETD2o      | Hs.631789   | NM_031915  | −2.40050    | 0.00621  | Histone methyltransferase     | Repressive             |

*a*DOT1-like, histone H3 methyltransferase (S. cerevisiae).

*b*DAZ interacting protein 3, zinc finger.

*c*Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila).

*d*Ribosomal protein S6 kinase, 90 kDa, polypeptide 3.

*e*SET domain containing 1B.

*f*SET domain containing 2.

*g*Aurora kinase B.

*h*DNA (cytosine-5-)methyltransferase 3 beta.

*i*Establishment of cohesion 1 homolog 1 (S. cerevisiae).

*j*Histone acetyltransferase 1.

*k*Histone deacetylase 1.

*l*Histone deacetylase 5.

*m*Histone deacetylase 11.

*n*Ribosomal protein S6 kinase, 90 kDa, polypeptide 5.

*o*SET domain, bifurcated 2.
high SETD1B/high ZEB1 expression seems to be useful for defining a high risk subgroup of tumors (logrank $p = 0.018$; overall survivals = 47.5%; Fig. 4d) with unfavorable prognosis whereby ZEB1 seems to be the more dominant factor. Low SETD1B/high ZEB1 cases ($n = 43$) showed an overall survival of 56.5% and high SETD1B/low ZEB1 ($n = 43$) presented an overall survival of 74.5%. Interestingly 83.3% of the 43 patients from the low/low group survived after 5 years of follow-up. Thus, we suggest that the ZEB1-SETD1B axis has strong prognostic value for CRC patients.

ZEB1 induces a SETD1B dependent positive feedback loop

Recently, it has been shown that an interaction between the EMT transcription factor TWIST1 and the chromatin modifier NSD2, a histone methyltransferase, is crucial for transcriptional regulation of TWIST1 itself in prostate cancer. Thus, we wanted to analyze if promoter demethylation or SETD1B-dependent histone mark could be responsible for the transcriptional upregulation of ZEB1 in EMT cells. For this, we examined 7 CpG islands in the ZEB1 promoter 100–300 bp upstream of the transcription site (Fig. 5a). Both cell lines were unmethylated for this region suggesting that ZEB1 transcriptional upregulation is not caused by demethylation of its promoter. Next, we again chose ChIP experiments to examine the chromatin state at the ZEB1 promoter. Interestingly we were able to show an increase in H3K4me3 methylation in the promoter region of ZEB1 in p21$^{--}$ cells compared to the WT cells (Fig. 5b, c), Presence of this active histone mark is consistent with increased ZEB1 expression in p21$^{--}$ cells. Next we performed a SETD1B si transfection in HCT116 p21$^{--}$ cells. We observed an effective downregulation of SETD1B protein and the corresponding H3K4me3 code at 24 h. ZEB1 protein levels were decreased at 24 and 48 h, whereas the E-Cadherin protein levels were nearly unchanged. Interestingly the Vimentin protein levels decreased at both time points (Fig. 5f). To analyze if the SETD1B mediated active histone code is associated with...
the high Vimentin expression in p21−/− cells we extended the ChIP experiment. Indeed, we confirmed an enrichment of the H3K4me3 code at the Vimentin promoter with a concomitant promoter demethylation (Fig. 5c and Suppl. Fig. 2).

Since it is known that transcriptional activity of ZEB1 is mainly mediated by its recruitment of co-repressors or co-activators we were led to the question if ZEB1 might recruit SETD1B into a protein complex. Towards this, we modeled the complex of (ZEB1-SETD1B) and analyzed the energy profiles and interactions between these two proteins (Fig. 5d) in HCT and HCT p21−/− cells. Our structural modeling showed that the binding energy of the (ZEB1-SETD1B) complex was decreased by ~20% in

Fig. 3 p21−/− cells show an upregulation of ZEB1 and SETD1B in vivo. a Representative light microscopy images of fixed and extracted CAM tumors (HCT WT and HCT p21−/−); Magnification = 100x; Scale bar = 2 mm; n ≥ 8. Tumor volume calculation in HCT CAM tumors (HCT WT and HCT p21−/−); n ≥ 8. b Representative immunohistochemical stainings on FFPE CAM sections for HE (Magnification = 200x and 600x); Scale bar = 100 and 50 μm, n ≥ 8. c Tumor mitosis calculation in HCT CAM tumors (HCT WT and HCT p21−/−); n ≥ 8 (**p < 0.001). d Representative immunohistochemical stainings on FFPE sections for p21 and ZEB1 of CAM tumors (HCT WT and HCT p21−/−); Magnification = 400x; Scale bar = 100 μm; n ≥ 8. e Dot plot analysis of expression intensities (IRS score) for immunohistochemical stainings of p21 and ZEB1 of CAM tumors (HCT WT and HCT p21−/−); Magnification = 400x; Scale bar = 100 μm; n ≥ 8. f Western blot analysis of unfixed CAM tumor samples confirming in vitro data; n = 4. *The same membrane was used for both proteins. g Protein expression measured by western blot of unfixed CAM tumor samples; n = 4 (∗p < 0.05). h Protein expression measured by western blot of unfixed CAM tumor samples; n = 4 (∗p < 0.05).
p21−/− cells (−1410.5 kcal/mol) compared to the energy of the complex in HCT cells (−1137.5 kcal/mol) showing a stabilization of this complex in EMT cells. Several hydrophobic amino acid residues (730–786) in the Proline rich regions of SETD1B were found to interact with Threonines, Leucines, Cysteines, and Methionines in the region between the Zinc finger domain and homeobox domain of ZEB1 and between the homeobox domain and the second zinc finger domain of ZEB1 (data not shown). We performed a co-immunoprecipitation experiment using the SETD1B antibody and detected ZEB1 in the precipitate (Fig. 5g). Vice versa using two different ZEB1 antibodies we were not able to show any SETD1B signal in the precipitate. Nevertheless, proximity ligation assay verified the existence of the protein complex between SETD1B and ZEB1 in HCT and HCT p21−/− cells as proposed in the in silico modeling (Fig. 5h). As a negative control we used a membrane bound protein, EpCAM, and did not find any signals of SETD1B and EpCAM binding in both cell lines showing the specificity of the experimental procedure (Fig. 5h). Since we did not detect significantly more interaction signals in p21−/− cells we suggest that the additional ZEB1 and SETD1B molecules might also act in other protein complexes independent of the already existing ZEB1/SETD1B protein complex. In summary, our findings support the assumption that ZEB1 selectively recruits chromatin modifiers in a promoter-specific manner.

Figure 6a recapitulates in a regulatory network all the interactions relevant for the regulation of SETD1B in the context discussed. The key element of the system is the double positive feedback loop between ZEB1 and SETD1B...
Fig. 5 SETD1B reinforces ZEB1 expression. a Representative pyrosequencing analysis of HCT cell lines for the CpG island in the ZEB1 promoter region; n ≥ 2. This data shows that the ZEB1 promoter is hypo-methylated in both cell lines, indicating that the loss of p21 does not affect the methylation status of the ZEB1 promoter and hence the transcriptional upregulation of ZEB1 is not caused by demethylation. b Schematic display of promoter regions for ZEB1 with respective primer pairs (gray) and transcription start site (TSS) (red arrow). c ChIP analysis of H3K4me3 binding capacity to Vimentin and ZEB1 promoter region; n = 3 (*p < 0.05). d The complex of (ZEB1-SETD1B) was formed by docking the individual proteins using the Protein–Protein docking tool ClusPro19,20. The complex with the least energy was chosen for the analysis of interactions between the proteins considered. The cluster scores of the complexes from the ClusPro server were used to understand the energy profiles of the (ZEB1-SETD1B) complex. The ionic, hydrophobic, hydrogen bond interactions were identified and analyzed using the protein interaction calculator (PIC)21 and are summarized in the Supplements. All renderings were done using CHIMERA22. e CpGenome universal methylated DNA (MerckMillipore) was used as a positive control and unmethylated human placenta DNA was used as a negative control. f mean ± s.e.m. Unpaired two-tailed Student’s t-test. g Representative images of HCT p21–/– cells upon SETD1B knockdown after siRNA transfection for 24 h; phase contrast magnification = 200x; Scale bar = 100 μm; n ≥ 4. h Representative western blot analysis of SETD1B, E-Cadherin, Vimentin, ZEB1, and H3K4me3 in HCT p21–/– cells upon SETD1B knockdown after siRNA transfection. Fold expression (western blot) is represented relative to GAPDH loading control; n ≥ 2. i Co-IP of endogenous SETD1B and ZEB1 in HCT p21–/– cells showing co-precipitated ZEB1 after SETD1B immunoprecipitation. HCT p21–/– cell lysates were used as a control lysate; Ctrl IgG control. j Representative images of proximity ligation assay for SETD1B and ZEB1 in HCT WT and HCT p21–/–; scale: 25 μm; 400x magnification, fluorescence image (blue: DAPI to visualize the nucleus, red: to visualize the protein complex) is computer enlarged. White/red dots represent the protein interaction.

(ZEB1 → SETD1B → ZEB1/H3K4me3 → ZEB1). Through this loop each protein can reinforce the activity/expression of the other. This can amplify the activation of the circuit: small/transient activation of ZEB1 can provoke strong/permanent activation of the circuit. Additionally, the network includes a coherent feedforward loop. In this loop, ZEB1 directly promotes the expression of SETD1B. The different regulation patterns of the ZEB1-SETD1B circuit under the wildtype (Fig. 6b) and tumorigenic (Fig. 6c) conditions are shown as discussed. In the wildtype case, the system works as a coherent feedforward regulating the expression of SETD1B and can
act as a noise buffer system under ZEB1 signaling noise. In solid lines, we represent how short-duration, low-intensity stimulation triggers a short-duration, low-intensity activation of ZEB1 and SETD1B. In the scheme on the right under tumorigenic conditions (Fig. 6c) that promote an overexpression or overactivation of ZEB1, the positive feedback loop between ZEB1 and SETD1B can get triggered. This would induce an irreversible enhancement in the expression and activity of both molecules under transient stimulation of ZEB1 (solid lines). Under these conditions, the coherent feedforward loop gets activated. This behavior is totally different to that of the system under physiological conditions, represented in dashed lines.

**Discussion**

With this study, we describe that ZEB1 causes severe alterations in the expression patterns of chromatin modifying enzymes. We report that the ZEB1-mediated upregulation of histone methyltransferase SETD1B is stabilizing ZEB1-mediated EMT through different feedback mechanisms, in which the key element seems to be a positive feedback loop between ZEB1 and SETD1B. Through this loop each protein can reinforce the activity/expression of the other. Thus, our findings fit very well with the concept of EMT induction as a programmed epigenetic switch 30.

The EMT transcription factor ZEB1 has multiple functions and if it is acting as a transcriptional repressor or activator strongly depends on the tumor type. There is a variety of co-repressors or co-activators that ZEB1 is interacting with. P300, DOT1L, Tip60, and PCAF are histone acetyltransferases that are recruited to activate gene expression, whereas interactions with CtBP, HDAC1, and SIRT1 are rather repressing gene expression 10,11,26,31. Interestingly, treatment with HDAC inhibitors was found to effectively suppress EMT 32,33.

Other ZEB1 interaction partners are the H3K4 demethylase LSD1 and BRG1 as a subunit of the SWI/SNF complex 33,34. In accordance with and highly conclusive from these data we showed that ZEB1 induction in the mesenchymal HCT p21−/− cells led to a massive dysregulation of epigenetic players. Yet, there was no obvious preference for chromatin modifiers that are majorly activating (upregulated: KMT2A, RPS6KA3, SETD1B, and SETD2; downregulated: AURKB, ESCO2, HAT1, and RP56KA5) or repressing factors (upregulated: DOT1L, DZIP3; downregulated: DNMT3B, HDAC1, HDAC5, HDAC11, and SETDB2). In our study we focused on SETD1B, a histone methyltransferase that contributes to

---

**Fig. 6 ZEB1 regulates SETD1B via a regulatory circuit integrated by feedback and feedforward loops.** a The system recapitulates in a regulatory network all the interactions relevant for the interplay between SETD1B and ZEB1 in the context discussed. The key element of the system is the double positive feedback loop between ZEB1 and SETD1B (ZEB1 → SETD1B → ZEB1/H3K4me3 → ZEB1). Through this loop each protein can reinforce the activity/expression of the other. This can amplify the activation of the circuit. b Under low transient stimulation (S) of ZEB1, the circuit responds with transient, low level activation even in the absence of p21. c The structure of the circuit suggests a medium but transient stimulation (S) of ZEB1. This activation can provoke an irreversible enhancement in the expression and activity of both molecules via triggering of SETD1B and feedback-regulating ZEB1 activation. This in turn may trigger the EMT phenotype by consistent, long-lasting inhibition of epithelial marker E-Cadherin. In solid red lines, we represent the long-lasting activation of the circuit, while the black dashed lines represent the transient activation of the circuit that would appear in case of disruption of the positive feedback loop.
the epigenetic control of chromatin structure by specifically methylating Lys4 at histone H3.

It is known that mutations of SETD1B play a role in tumorigenesis of gastric and colorectal cancers with MSI. When we analyzed the mutation frequency of the 526 colorectal cancer patients reported in the TCGA PanCancer Atlas (www.cbioportal.org) we found 6% of SETD1B mutant cases (36 samples) with 26 cases had a mutation load higher than 1000. Recurrent missense mutations were reported in known protein domains such as the RNA recognition motif, the N-SET domain and the catalytic SET domain. Nevertheless, the pathogenic role of the single mutation variants and their clinical significance remain mostly unclear. It also remains unclear, which steps of cancer development are affected or regulated by SETD1B. Moreover, there is only speculation about SETD1B’s role in cancer and EMT. From clinical data we extracted the worst prognosis when both, ZEB1 and SETD1B were highly expressed whereas in the low/low group nearly all colorectal cancer patients survived the first 5 years after surgery. For endometrial carcinomas it was reported that for SETD1B mutant cases a higher myometrial invasion can be predicted. In clear cell renal cell carcinomas SETD1B overexpression could discriminate metastatic from non-metastatic tumors.

The SETD1B specific epigenetic modification of a trimethylated lysine 4 at histone 3 (H3K4me3) is well-accepted as a marker for transcriptionally active gene promoters. The observed enrichment of the H3K4me3 histone modification was induced by ZEB1-dependent induction of SETD1B expression at the ZEB1 promoter itself showing a novel feedback reinforcement loop for ZEB1. Furthermore, SETD1B seems to trigger the expression of Vimentin creating an active chromatin status with concomitant demethylation of the Vimentin gene promoter. Also, for bivalent genes during ES differentiation to neuronal precursor cells the H3K4me3 modification is known to become enriched at specific genes. Our finding of a higher H3K4me3 code in EMT cells would fit with others who showed that an ablation of the H3K4 demethylase LSD1 in breast carcinoma cells led to an increased migration and metastasis. In colorectal cancer, alterations in H3K4me3 levels were shown to be associated with tumor initiation. The SETD1B-H3K4me3 epigenetic axis has been reported to contribute to increased iNOS expression in tumor-induced myeloid-derived suppressor cells to render T cell low responsive to antigen stimulation. There is a very similar regulatory cascade in leukemia cells, where transcription factor NFKB recruits the MLL1 histone methyltransferase complex to activate NFKB target genes after TNF treatment. It was previously reported that SETD1B is a possible causative gene for the pathogenesis of the 12q24.3 deletion syndrome. In this regard patients with de novo SETD1B mutations showed signs of epilepsy, developmental delay, intellectual disability, and autism. From these few available literature reports we suggest that the regulation of the H3K4me3 mark is extremely complex and an increase of SETD1B expression could affect many different pathways.

In this study, we verified that ZEB1 acts in concert with SETD1B to direct EMT an important cellular plasticity program. For the first time, we give evidence that ZEB1 directly binds to SETD1B in a protein complex. In the p21−/− cells this complex seems to be redirected to EMT-associated promoters. We strongly believe that mesenchymal p21−/− cells represent a suitable model for mechanistic EMT-related studies leading here to the identification of our novel molecular network. Since our analysis tool was an isogenic tumor cell line originating from a microsatellite instable tumor the clinical data strengthen our results also for MSS tumors that are summarized in molecular subtypes CMS2, CMS3, and CMS4.

**Conclusions**

Here we describe a novel link between the EMT transcription factor ZEB1 and chromatin modification. For the first time we report that ZEB1 directly regulates the expression pattern of the histone methyltransferase SETD1B in colorectal cancer cells. Mechanistically we show that ZEB1 binds the promoter region of the SETD1B gene and that SETD1B dependent active H3K4me3 histone code seems to open the ZEB1 promoter, forming a positive feedback loop. Our study indicates a new example of an activator role of ZEB1 for one of the diverse functions that tumors acquire during EMT. Furthermore, we demonstrate pathophysiological relevance of our findings.

**Acknowledgements**

The present work was performed in partial fulfillment of the requirements for obtaining the degree Dr. rer. nat. for PL at the FAU Erlangen-Nürnberg. We thank Adrian Koch, Christa Winkelmann, and Ingrid Mons for their excellent technical support. This article is partly based upon work from COST Action CA17118, which was supported by COST (European Cooperation in Science and Technology, www.cost.eu). PL and RSS were supported by the Emerging Fields Initiative “Cell Cycle in Disease and Regeneration” (CYDER) of the Friedrich Alexander University (Erlangen-Nürnberg, Germany). PL was supported by a traveling grant of the Boehringer-Ingelheim-Foundation. SP’s position was directly funded by the University Hospital, FAU Erlangen-Nürnberg.

**Author details**

1. Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Bavaria, Germany.
2. Experimental Tumorpathology, Universitätsklinikum Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Bavaria, Germany.
3. Laboratory of Systems Tumor Immunology, Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Bavaria, Germany.
4. Institute of Bioinformatics and Applied Biotechnology (IBAB), Bangalore, India.
5. Experimental Medicine I, Nikolaus-Fiebiger-Center for Molecular Medicine, Comprehensive Cancer Center, Universitätsklinikum Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Data availability
The RT² Profiler PCR Arrays Data Set (PAHS-0852) was submitted to the Gene Expression Omnibus (GEO) data repository as a Sub-Series under the accession number GSE107664 (PAHS-0852). Data availability is given in Materials and Methods as well as Supplementary section.

Conflict of interest
The authors declare that they have no conflict of interest.

Consent for publication
All authors have agreed to publish this paper.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information
accompanies this paper at (https://doi.org/10.1038/s41419-020-2340-4).

Received: 12 April 2019 Revised: 5 December 2019 Accepted: 6 December 2019
Published online: 24 February 2020

References
1. Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420–1428 (2009).
2. Sun, L. & Fang, J. Epigenetic regulation of epithelial-mesenchymal transition. Cell Mol. Life Sci. 73, 4449–4515 (2016).
3. Sánchez-Tillo, E. et al. Expanding roles of ZEB factors in tumorigenesis and tumor progression. Am. J. Cancer Res. 1, 897–912 (2011).
4. Zhang, P., Sun, Y. & Ma. L. ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle 14, 481–487 (2015).
5. Karhitla, P. et al. Vimentin, Zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumor phenotype. Breast Cancer Res. Treat. 138, 81–90 (2013).
6. Liu, Y. et al. Different thresholds of ZEB1 are required for Ras-mediated tumour initiation and metastasis. Nat. Commun. 5, 5660 (2014).
7. Spaderna, S. et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res. 68, 537–544 (2008).
8. Wellner, U. et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 11, 1487–1495 (2009).
9. Krebs, A. M. et al. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat. Cell Biol. 19, 518–529 (2017).
10. Byles, V. et al. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene 31, 4619–4629 (2012).
11. Aghdasi, A. et al. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut 61, 439–448 (2012).
12. Li, X. L. et al. A p21-ZEB1 complex inhibits epithelial-mesenchymal transition through the MicroRNA 183-96-182 cluster. Mol. Cell Biol. 34, 533–550 (2014).
13. Ribeiro, A. S. & Paredes, J. P-Cadherin linking breast cancer stem cells and invasion: a promising marker to identify an ‘Intermediate/Metastable’ EMT state. Front Oncol. 4, 371 (2014).
14. El-Baba, C. et al. Thymoquinone-induced conformational changes of PAK1 interrupt prosurvival MEK-ERK signaling in colorectal cancer. Mol. Cancer 13, 201 (2014).
15. Doeger, C. A. et al. Early-stage epigenetic modification during somatic cell reprogramming by Pernp1 and Tert. Nature 488, 652–653 (2012).
16. Mauhted, A. et al. Cytoplasmic p21 mediates S-Fluorouracil resistance by inhibiting pro-apoptotic Chk2. Cancers 10, 373 (2018).
17. Šall, A. & Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779–815 (1993).
18. Yang, J. et al. The I-TASSER suite: protein structure and function prediction. Nat. Methods 12, 7–8 (2015).
19. Comeau, S. R. Catchell, D. W., Vajda, S. & Camacho, C. J. ClusPro: a fully automated algorithm for protein-protein docking. Nucleic Acids Res. 32, W96–W99 (2004).
20. Kozaiko, D. et al. The ClusPro web server for protein-protein docking. Nat. Protoc. 12, 255–278 (2017).
21. Tina, K. G., Bhadra, R. & Sinivasan, N. PIC: protein interactions calculator. Nucleic Acids Res. 35, W473–W476 (2007).
22. Pettersen, E. F. et al. UCSF Chimera—a visualization system for exploratory research and analysis. J. Comp. Chem. 25, 1605–1612 (2004).
23. Serrano-Gómez, S. J., Mätevys, M. & Alahari, S. K. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol. Cancer 15, 18 (2016).
24. Chang, C. J. et al. p53 regulates epithelial–mesenchymal transition and stem cell properties through modulating miRNAs. Nat. Cell Biol. 13, 317–323 (2011).
25. Dong, P. et al. Mutant p53 gain-of-function induces epithelial–mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 32, 3286–3295 (2013).
26. Lehmann, W. et al. ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nat. Commun. 7, 10498 (2016).
27. Preca, B. et al. A novel ZEB1 HAS2 positive feedback loop promotes EMT in breast cancer. Oncotarget 8, 11350–11354 (2017).
28. Gunney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350–1356 (2015).
29. Espindola, T. et al. The histone methyltransferase MMSET/HASH1/ASH1L activates TWIST1 to promote an epithelial–mesenchymal transition and invasive properties of prostate cancer. Oncogene 32, 2882–2890 (2013).
30. Javid, S. et al. Dynamic chromatin modification sustains epithelial-mesenchymal transition following inducible expression of snail-1. Cell Rep. 5, 1679–1689 (2013).
31. Cho, M. H. et al. DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression. Nat. Commun. 6, 7821 (2015).
32. Phillip, C. J. et al. Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells. BMC Cancer 12, 145 (2012).
33. Shi, Y. et al. Coordinated histone modifications mediated by a CtBP corepressor complex. Nature 422, 735–738 (2003).
34. Sánchez-Tillo, E. et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodelling protein BRG1. Oncogene 29, 3490–3500 (2010).
35. Choi, Y. J. et al. Frameshift mutation of a histone methylation-related gene SETDB1 and its regional heterogeneity in gastric and colorectal cancers with high microsatellite instability. Hum. Pathol. 45, 1674–1681 (2014).
36. García-Sanz, P. et al. Chromatin remodelling and DNA repair genes are frequently mutated in endometrial endometrioid carcinoma. Int. J. Cancer 140, 1551–1563 (2017).
37. Kumar, A. et al. Expression and clinical significance of COMPASS family of histone methyltransferases in clear cell renal cell carcinoma. Gene 674, 31–36 (2018).
38. Yang, Y. & Wilson, M. J. Genome-wide analysis of H3K4me3 and H3K2me3 modifications throughout the mouse urogenital ridge at E11.5. Gene Reports 16, 100412 (2019).
39. Hino, S., Kohogi, K. & Nakao, M. Histone demethylase LSD1 controls the phenotypic plasticity of cancer cells. Cancer Sci. 107, 1187–1192 (2016).
40. Erroth, S. et al. Cancer associated epigenetic transitions identified by genome-wide histone methylation binding profiles in human colorectal cancer samples and paired normal mucosa. BMC Cancer 11, 450 (2011).
41. Wang, X. et al. MLL1, a H3K4 methyltransferase, regulates the TNFalpha-stimulated activation of genes downstream of NF-kappaB. J. Cell Sci. 125, 4058–4066 (2012).
42. Labonne, J. D. J. et al. An atypical 12q24.31 microdeletion implicates six genes including a histone demethylase KDM2B and a histone methyltransferase SETDB1 in syndromic intellectual disability. Hum. Genet. 135, 757–771 (2016).
43. Palumbo, O. et al. Microdeletion of 12q24.31: report of a girl with intellectual disability, stereotypies, seizures and facial dysmorphisms. Am. J. Med. Genet. Part A 167A, 438–444 (2014).
44. Hiraide, T. et al. De novo variants in SETDB1 are associated with intellectual disability, epilepsy and autism. Hum. Genet. 137, 95–104 (2018).